You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Atorvastatin hemicalcium salt
Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 577.67. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.73 mL||8.66 mL||17.31 mL|
|5 mM||0.35 mL||1.73 mL||3.46 mL|
|10 mM||0.17 mL||0.87 mL||1.73 mL|
|50 mM||0.03 mL||0.17 mL||0.35 mL|
References are publications that support the biological activity of the product.
Istvan et al (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 1160 PMID: 11349148
Vaughan et al (2004) Update on STAT: 2003. Circulation 110 886 PMID: 15313959
Santodomingo-Garzon et al (2006) AtoVas inhibits inflammatory hypernociception. Br.J.Pharmacol. 149 14 PMID: 16865092
Turner et al (2007) Comparison of the efficacies of five different STAT on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J.Cardiovasc.Pharmacol. 50 458 PMID: 18049315
If you know of a relevant reference for Atorvastatin hemicalcium salt, please let us know.
View Related Products by Product Action
Keywords: Atorvastatin hemicalcium salt, Atorvastatin hemicalcium salt supplier, HMG-CoA, reductases, inhibitors, inhibits, cholesterol, biosynthesis, LDL, Pfizer, statins, Lipitor, Reductase, 3776, Tocris Bioscience
1 Citation for Atorvastatin hemicalcium salt
Citations are publications that use Tocris products. Selected citations for Atorvastatin hemicalcium salt include:
Rojo-Arreola et al (2014) Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One 9 e87594 PMID: 24489942
Do you know of a great paper that uses Atorvastatin hemicalcium salt from Tocris? Please let us know.
Reviews for Atorvastatin hemicalcium salt
Average Rating: 5 (Based on 1 Review.)
Have you used Atorvastatin hemicalcium salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.